Celcuity

Celcuity is a clinical-stage biotechnology company developing molecularly targeted therapies for solid tumor cancers driven by PI3K pathway dysregulation. Its lead candidate, gedatolisib, is a pan-PI3K/mTOR inhibitor being evaluated in Phase 3 trials for HR+/HER2- advanced breast cancer and has received an FDA NDA acceptance. The company also develops companion diagnostics to identify patients most likely to benefit from its precision oncology therapies.